[1]
|
K. Eichler, S. Hempel, J. Wilby, et al., “Diagnostic Value of Systematic Biopsy Methods in the Investigation of Prostate Cancer: A Systematic Review,” Journal of Urology, Vol. 175, No. 5, 2006, pp. 1605-1612.
doi;10.1016/S0022-5347(05)00957-2
|
[2]
|
V. Scattoni, A. Zlotta, R. Montironi, C. Schulman, P. Rigatti and F. Montorsi, “Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the Literature,” European Urology, Vol. 52, No. 5, 2007, pp. 1309-1322.
doi;10.1016/j.eururo. 2007.08.006
|
[3]
|
A. Heidenreich, J. Bellmunt, M. Bolla, et al., “EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease,” European Urology, Vol. 59, No. 1, 2011, pp. 61-71.
doi;10.1016/j.eururo.2010.10.039
|
[4]
|
T. A. Stamey F. S. Freiha, J. E. McNeal, et al., “Localized Prostate Cancer. Relationship of Tumor Volume to Clinical Significance for Treatment of Prostate Cancer,” Cancer, Vol. 71, Supplement S3, 1993, pp. 933-938.
doi;10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO; 2-L
|
[5]
|
J. I. Epstein, P. C. Walsh, M. Carmichael, et al., “Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (T1c) Prostate Cancer,” JAMA, Vol. 271, No. 5, 1994, pp. 368-374.
doi;10.1001/jama.1994.03510290050036
|
[6]
|
R. Chou, J. M. Croswell, T. Dana, et al., “Screening for Prostate Cancer: A Review of the Evidence for the US Preventive Services Task Force,” Annals of Internal Medicine, Vol. 155, No. 11, 2011, pp. 762-771.
doi;10.7326/0003-4819-155-11-201112060-00375
|
[7]
|
F. H. Schroder, J. Hugosson, M. J. Roobol, et al., “Screening and Prostate-Cancer Mortality in a Randomized European Study,” The New England Journal of Medicine, Vol. 360, No. 13, 2009, pp. 1320-1328.
doi;10.1056/NEJMoa0810084
|
[8]
|
F. H. Schroder, J. Hugosson, M. J. Roobol, et al. and ERSPC Investigators, “Prostate-Cancer Mortality at 11 Years of Follow-Up,” The New England Journal of Medicine, Vol. 366, No. 11, 2012, pp. 981-990.
doi;10.1056/NEJMoa1113135
|
[9]
|
M. Bul and F. H. Schroder, “Screening for Prostate Cancer—The Controversy Continues, but Can It Be Resolved?” Acta Oncologica, Vol. 50, No. S1, 2011, pp. 4-11.
doi;10.3109/0284186X.2010.522197
|
[10]
|
G. P. Haas, N. B. Delongchamps, R. F. Jones, et al., “Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence,” Journal of the National Cancer Institute, Vol. 99, No. 19, 2007, pp. 1484-1489. doi;10.1093/jnci/djm153
|
[11]
|
P. Troncoso, R. J. Babaian, J. Y. Ro, et al., “Prostatic Intraepithelial Neoplasia and Invasive Prostatic Adenocarcinoma in Cystoprostatectomy Specimens,” Urology, Vol. 34, Supplement 6, 1989, pp. 52-56.
|
[12]
|
J. I. Epstein, W. C. Allsbrook Jr., M. B. Amin, et al., “The 2005 International Society of Urological Pathology (ISUP) Concensus Conference on Gleason Grading of Prostatic Carcinoma,” The American Journal of Surgical Pathology, Vol. 29, No. 9, 2005, pp. 1228-1242.
doi;10.1097 /01.pas. 0000173646.99337.b1
|
[13]
|
M. Noguchi, T. A. Stamey, J. E. McNeal, et al., “Assessment of Morphometric Measurements of Prostate Carcinoma Volume,” Cancer, Vol. 89, No. 5, 2000, pp. 1056-1064. doi;10.1097/01.pas. 0000173646.99337.b1
|
[14]
|
A. R. Schned, K. J. Wheeler, C. A. Hodorowski, et al., “Tissue-Shrinkage Correction Factor in the Calculation of Prostate Cancer Volume,” The American Journal of Surgical Pathology, Vol. 20, No. 12, 1996, pp. 1501-1506.
doi;10.1097/00000478-199612000-00009
|
[15]
|
A. R. Patel, J. S. Jones, J. Rabets, et al., “Parasagittal Biopsies Add Minimal Information in Repeat Saturation Prostate Biopsy,” Urology, Vol. 63, No. 1, 2004, pp. 87-89. doi;10.1016/ j.urology. 2003.08.040
|
[16]
|
R. K. Nam, R. Saskin, Y. Lee, et al., “Increasing Hospital Admission Rates for Urological Complications after Transrectal Ultrasound Guided Prostate Biopsy,” Journal of Urology, Vol. 183, No. 3, 2010, pp. 963-968.
doi;10.1016/j.juro.2009.11.043
|
[17]
|
M. J. Roobol, R. C. N. Van Den Bergh, T. Wolters, et al., “Serum PSA Levels, Number of Prostate Biopsies and Number and Characteristics of Prostate Cancers Detected in Three Consecutive Screening Visits Using a PSA Based Biopsy Indication,” European Urology, Vol. 7, No. 3, 2008, p. 199. doi;10.1016/S1569-9056(08)60509-6
|